This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Prohibitin 1 (PHB1)	*In vitro* and mouse studies suggest that inhibiting PHB1 could help treat paclitaxel-resistant cancers. Proteomics analysis showed that PHB1 was overexpressed in two paclitaxel-resistant cancer cell lines compared with nonresistant cancer cell lines. In resistant cell lines and mice with resistant xenograft tumors, PHB1-targeting small interfering RNA plus paclitaxel led to more apoptosis and greater reductions in tumor growth than paclitaxel alone. Ongoing work includes identifying circulating markers of cancers that are resistant to paclitaxel and other taxanes, and developing therapeutics to treat the resistant tumors. ***SciBX*** **3(5); doi:10.1038/scibx.2010.144** **Published online Feb. 4, 2010**	Patented by Children's Hospital Boston; available for licensing	Patel, N. *et al. Proc. Natl. Acad. Sci. USA*; published online Jan. 25, 2010; doi:10.1073/pnas.0910649107 **Contact:** Bruce R. Zetter, Children's Hospital Boston, Boston, Mass. e-mail: bruce.zetter@childrens.harvard.edu